VNDA - Vanda Pharmaceuticals Inc Volatility & Greeks
This article provides a detailed overview of Vanda Pharmaceuticals Inc. (VNDA), including its latest stock performance, key financial metrics, volatility, and options Greeks. It covers market capitalization, recent earnings data, insider and institutional ownership, and various performance indicators.
McDermott Represents Vanda Pharmaceuticals Inc. on Acquisition of PONVORY®
McDermott Will & Emery represented Vanda Pharmaceuticals Inc. in its acquisition of US and Canadian rights to PONVORY®, a treatment for relapsing forms of multiple sclerosis. The McDermott deal team was led by Kristian Werling with support from numerous other attorneys. This acquisition allows Vanda to expand its portfolio in the biopharmaceutical sector.
Here’s Why H.C. Wainwright Remains a Buy on Vanda Pharmaceuticals (VNDA)
H.C. Wainwright has reiterated a Buy rating for Vanda Pharmaceuticals (VNDA) with a $21 price target, following an update on the company's FDA approval process for HETLIOZ as a jet lag treatment. The FDA has granted Vanda a formal hearing, a rare event, to discuss the drug's approval after an initial refusal. This hearing, expected before year-end, could allow Vanda to generate branded prescription sales for a new jet lag indication, largely protected from generic competition.
Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) dropped from Russell 2000 Defensive Index
Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) has been removed from the Russell 2000 Defensive Index. This news comes amidst other recent updates for the biopharmaceutical company, including its Q1 2026 earnings call, raising its full-year 2026 revenue guidance, and the U.S. commercial availability of its new motion sickness drug, Nereus. Vanda Pharmaceuticals is actively involved in developing and commercializing therapies for various unmet medical needs, with a pipeline that includes drugs for schizophrenia, sleep-wake disorders, multiple sclerosis, and motion sickness.
Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) dropped from Russell 2000 Value-Defensive Index
Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) has been removed from the Russell 2000 Value-Defensive Index. This announcement follows several recent company updates, including its Q1 2026 earnings call, raised revenue guidance, and the U.S. launch of its motion sickness drug Nereus. The biopharmaceutical company remains focused on developing and commercializing therapies for various medical needs.
Price to book forward of Vanda Pharmaceuticals Inc. – NASDAQ:VNDA
This article provides financial information for Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), specifically focusing on its "Price to book forward" metric. It appears to be a financial data snippet from TradingView, indicating market closed status and offering an overview of financials, news, and other related data for the company.
Price to earnings forward of Vanda Pharmaceuticals Inc. – FWB:VM4
This article provides financial information for Vanda Pharmaceuticals Inc. (FWB:VM4), specifically focusing on its price-to-earnings forward ratio. The content lists the company's stock exchange details, and indicates that the market was closed with no trades recorded at the time of publication.
Price to earnings forward of Vanda Pharmaceuticals Inc. – NASDAQ:VNDA
This article provides the "Price to earnings forward" value for Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), indicating it's a financial metric available on TradingView. The content primarily focuses on presenting this specific data point for the company, accessible through its financial overview.
Enterprise value to EBITDA forward of Vanda Pharmaceuticals Inc. – FWB:VM4
The article presents the Enterprise Value to EBITDA forward for Vanda Pharmaceuticals Inc. (FWB:VM4) on the Frankfurt Stock Exchange. It provides financial data for this specific metric and indicates that the market was closed with no trades at the time of publication. The content is primarily a data placeholder from TradingView, offering a snapshot of a financial metric.
Enterprise value to revenue forward of Vanda Pharmaceuticals Inc. – LSX:A0JJT3
This article focuses on the "Enterprise value to revenue forward" metric for Vanda Pharmaceuticals Inc. (LSX:A0JJT3). It is presented within the context of financial data available on TradingView, specifically under the company's financials section. The content primarily lists and links various sections of the TradingView platform related to market data, community, and trading tools, rather than providing a detailed analysis of the metric itself.
Gastroparesis Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharma, Ironwood Pharma, Takeda
This report from DelveInsight highlights the Gastroparesis treatment pipeline for 2026, detailing over 10 therapies from 8+ companies including CinDome Pharma, Evoke Pharma, and Vanda Pharmaceuticals. The report provides an overview of clinical trials, mechanisms of action, and recent milestones, such as positive Phase IIb trial results for naronapride and completed patient enrollment for CinDome Pharma's deudomperidone (CIN-102) in gastroparesis studies. The evolving landscape reflects efforts to address the significant unmet medical need for long-term gastroparesis treatments.
Vanda Pharmaceuticals (VNDA) Short Interest & Short Float | Updated Jun 2026
Vanda Pharmaceuticals (VNDA) saw a 2.61% increase in its short interest, reaching 6.99 million shares sold short as of June 15, 2026, representing 13.01% of its public float. The short interest ratio is currently 7.8 days to cover, suggesting it would take approximately 7.8 days to cover all short positions based on average trading volume. This data indicates a significant level of bearish sentiment among investors towards VNDA.
Vanda Pharmaceuticals Inc. Actuals & Estimates (NASDAQ:VNDA)
This article provides an overview of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) stock performance, financials, and analyst forecasts. It covers key metrics like current price, market capitalization, earnings, revenue, and future price predictions from analysts, along with historical highs and lows. The company's next earnings report is anticipated on August 5, 2026, and the stock currently has a "sell" signal according to technical analysis for today and the next month.
VNDA Stock Rallies After-Hours As FDA Approves Schizophrenia, Bipolar Disorder Drug
Vanda Pharmaceuticals Inc. (VNDA) shares jumped 38% after hours following FDA approval of its Bysanti tablets for treating manic or mixed episodes associated with bipolar I disorder and schizophrenia in adults. Bysanti is expected to be available in Q3 2026 and is also being tested for treatment-resistant major depressive disorder. This marks Vanda's second drug approval in months, though an application for Hetlioz for jet lag was refused due to concerns about clinical trial protocols not fully replicating real-world conditions.
Vanda Now Looks To Public Hearing For Hetlioz In Jet Lag Disorder After Multiple FDA Rejections
Vanda Pharmaceuticals has secured a formal evidentiary public hearing from the FDA to review the refusal of its supplemental new drug application for Hetlioz in treating jet lag disorder. This is a rare move by the FDA, as such hearings for drug approvals have not been granted in over 40 years, according to Vanda. The company has faced multiple rejections for this indication, citing the FDA's concerns that clinical trials did not fully replicate real-world jet travel conditions.
Vanda Pharmaceuticals Inc (VNDA) Valuation: PE, PB & Fair Value Analysis
Vanda Pharmaceuticals Inc (VNDA) currently holds a valuation score of 7.67, placing it 211th out of 389 companies in the Biotechnology & Medical Research industry. Its P/E ratio is -1.48, which is significantly below its recent high and above its recent low. Key valuation metrics like P/E, P/B, P/S, and P/CF ratios have not been fully disclosed by the company.
Vanda Pharmaceuticals Inc (VNDA) Financial Health: Profitability & Balance Sheet Analysis
Vanda Pharmaceuticals Inc (VNDA) currently holds a financial score of 7.53, placing it 110th in the Biotechnology & Medical Research industry. Despite a weak financial status overall, the company shows high operating efficiency, with its latest quarterly revenue increasing by 3.35% and net profit soaring by 64.67% year-over-year. Key financial metrics like cash and cash equivalents, total assets, total liabilities, and free cash flow were mentioned, though detailed data for some sections were not yet disclosed.
GW Athletics Names Vanda Pharmaceuticals First Official Jersey Patch Partner
GW Athletics has announced a landmark partnership with Vanda Pharmaceuticals, making it the first official jersey patch partner in the program's history. This agreement, the largest corporate partnership for GW Athletics, will feature the Vanda logo on all 20 Revolutionaries teams' uniforms, enhancing visibility and providing significant revenue for student-athlete resources. The collaboration highlights Vanda's strong ties to the university, with its headquarters on campus and led by GW alumni.
Vanda Pharmaceuticals Mallorca Championships 2026: Draws, dates, history & all you need to know
The article provides a comprehensive guide to the 2026 Vanda Pharmaceuticals Mallorca Championships, an ATP 250 grass-court event. It details the dates, schedule, prize money, points distribution, and featured players like Luciano Darderi and Frances Tiafoe. The article also includes historical data, such as past champions and title records.
VNDA|Vanda Pharmaceuticals Inc|Price:6.000|Chg%:0.20
Vanda Pharmaceuticals Inc. (VNDA) fundamentals are stable with high growth potential, and its valuation is considered fair. Analysts have given it a "Buy" rating with a target price of 14.125, indicating a significant upside. The company is actively developing several drugs and has commercial products for neurological and sleep disorders.
Vanda Pharmaceuticals Inc (VNDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Vanda Pharmaceuticals Inc (VNDA), detailing its performance by business segment and geographical region. As of April 6, 2024, the company's total revenue was $216.10 million, with Fanapt contributing 54.28%, Hetlioz 33.05%, and PONVORY 12.67%. All of Vanda's reported revenue came from the United States.
Vanda Pharmaceuticals Inc (VNDA) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Vanda Pharmaceuticals Inc (VNDA)'s dividend and stock split history, noting that the company has not distributed dividends or had stock splits in the past five years. It presents current stock performance data, including its market cap and recent price movements. The page acts as a financial data hub for Vanda Pharmaceuticals.
Vanda Pharmaceuticals (VNDA) director granted 41,600 RSU shares vesting in 2027
Vanda Pharmaceuticals director Phaedra Chrousos was granted 41,600 restricted stock units (RSUs) as part of her equity compensation, with a vesting date of June 4, 2027, conditional on her continuous service to the company. This grant increases her direct holdings to 164,950 shares of Vanda Pharmaceuticals common stock. The transaction was a zero-cost grant, not a market purchase or sale.
Vanda (NASDAQ: VNDA) director awarded 41,600 RSU-based shares
Vanda Pharmaceuticals director Charles Cliff was granted 41,600 shares of common stock in the form of time-based Restricted Stock Units (RSUs) with a vesting date of June 4, 2027, contingent on his continuous service. These RSUs were awarded at no purchase price, increasing his direct holdings to 98,701 shares. This transaction was reported in a Form 4 filing, indicating an equity compensation rather than a market purchase.
Vanda Pharmaceuticals (VNDA) SVP McGuire reports RSU awards vesting through 2029
Vanda Pharmaceuticals SVP, GC and Secretary, Daniel Patrick McGuire, has filed an initial Form 3 reporting his beneficial ownership of common stock and Restricted Stock Units (RSUs). The RSU awards are set to vest in various installments between July 2026 and March 2029, contingent upon his continued employment. The filing provides details on the vesting schedules for different RSU awards and the total common stock holdings.
Vanda Pharmaceuticals (VNDA) director receives 41,600-share RSU grant
Vanda Pharmaceuticals Inc. director Anne Sempowski Ward received a grant of 41,600 restricted stock units (RSUs) at no cash cost. These RSUs are scheduled to vest in full on June 4, 2027, contingent on her continuous service to the company. Following this grant, Ward beneficially owns 160,667 shares of Vanda common stock directly.
80,000-share RSU grant to Vanda (VNDA) SVP and General Counsel
Vanda Pharmaceuticals (VNDA) reported that SVP, General Counsel, and Secretary Daniel Patrick McGuire received a grant of 80,000 restricted stock units (RSUs) at no cash cost. This grant, part of his equity compensation, vests in four equal annual installments starting June 4, 2027, contingent on his continued employment. Following this award, McGuire's direct ownership in Vanda Pharmaceuticals stands at 109,982 common shares.
Vanda Pharmaceuticals (VNDA) director receives 41,600-share RSU grant
Vanda Pharmaceuticals director Honore Tage received a grant of 41,600 Restricted Stock Units (RSUs), which will fully vest on June 4, 2027, provided continuous service to the company. This equity compensation award, valued at $0.00 per share, increases Tage's direct holdings to 135,069 common shares. The transaction was reported via a Form 4 SEC filing, indicating it's a compensation-related acquisition rather than an open-market purchase.
Vanda Pharmaceuticals (VNDA) grants director 41,600 RSUs vesting in 2027
Vanda Pharmaceuticals director Mitchell Stephen Ray has been granted 41,600 restricted stock units (RSUs) which will vest on June 4, 2027, provided he maintains continuous service to the company. This grant, valued at $0.00 per share, increases his direct holdings to 112,846 shares. The transaction was reported in an SEC Form 4 filing and is considered equity compensation rather than a market buy or sale.
Vanda Pharmaceuticals (VNDA) director receives 41,600-share RSU award
Vanda Pharmaceuticals director Richard W. Dugan was granted 41,600 Restricted Stock Units (RSUs) on June 4, 2026, which will vest 100% on June 4, 2027, provided he continues his service to the company. This equity compensation award increased his direct holdings in Vanda common stock to 219,054 shares. The grant price per share was $0.00, indicating it was not an open-market purchase.
Vanda Pharmaceuticals 2026 Annual Meeting Results: Director Elections, Auditor Ratification, and Plan Amendment Approved
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) has released the results of its 2026 annual shareholder meeting, which included the election of three Class II directors, the ratification of PricewaterhouseCoopers LLP as independent auditor, advisory approval of executive compensation, and an amendment to increase authorized shares under its 2016 Incentive Plan. Investors should closely monitor the implications of these results, particularly the potential for share dilution from the approved equity plan amendment and the notable votes against directors. The high shareholder participation rate highlights the importance of these decisions for VNDA's future governance and financial outlook.
Vanda (NASDAQ: VNDA) investors approve directors, auditor and equity plan shares
Vanda Pharmaceuticals Inc. announced the results of its 2026 annual stockholder meeting where shareholders approved the election of three Class II directors, ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm, and approved an amendment to the 2016 Equity Incentive Plan to increase shares authorized for issuance. Additionally, stockholders gave advisory, non-binding approval for the compensation of the company’s named executive officers. A quorum was established with approximately 80.7% of eligible common shares represented at the meeting.
Earnings call transcript: Vanda Pharmaceuticals Q1 2026 misses EPS forecast, stock drops
Vanda Pharmaceuticals Inc. reported a challenging Q1 2026, missing EPS forecasts with a loss of $0.82 against an expected $0.69, and revenue fell short at $51.7 million. The stock subsequently dropped by 13.53% in after-hours trading due to investor concerns over the miss and cautious outlook. Despite strong year-over-year Fanapt sales, HETLIOZ faced pressure from generic competition, while the new product NEREUS is expected to contribute positively later in the year.
Vanda gets orphan drug status in Japan for imsidolimab
Vanda Pharmaceuticals Inc. has received orphan drug designation from Japan's Ministry of Health, Labour and Welfare for its drug imsidolimab, intended for the treatment of generalized pustular psoriasis. This designation grants incentives like R&D subsidies and potential 10-year market exclusivity. Despite this positive development, the company recently reported first-quarter fiscal year 2026 financial results that missed analyst expectations, with an EPS loss of $0.82 and revenue of $51.7 million, raising investor concerns.
Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis
Vanda Pharmaceuticals has received Orphan Drug Designation from Japan's Ministry of Health, Labour and Welfare for imsidolimab, a monoclonal antibody for treating generalized pustular psoriasis (GPP). This designation provides development incentives and potential market exclusivity in Japan, where GPP affects approximately 2,200 people. Imsidolimab targets IL-36 receptor signaling, a pathway often dysregulated in GPP patients, especially within the Japanese population.
Japan gives special status to Vanda drug for rare, severe skin disease
Vanda Pharmaceuticals announced that Japan's Ministry of Health, Labour and Welfare granted orphan drug designation to imsidolimab for treating generalized pustular psoriasis (GPP). This status provides significant incentives, including R&D subsidies and potential market exclusivity for up to 10 years in Japan, following similar recognition in the United States. The designation addresses a high unmet medical need for approximately 2,200 GPP patients in Japan, reinforcing imsidolimab's global potential.
Vanda Pharmaceuticals Inc (VNDA) Stock Price, Quote, News & History
This article provides an overview of Vanda Pharmaceuticals Inc. (VNDA) stock, including its current price, key statistics, recent news, and financial data. It highlights the FDA approval of Bysanti for bipolar disorder and schizophrenia, which has positively impacted the stock. The article also includes analyst ratings, valuation metrics, and frequently asked questions about the company.
Vanda (VNDA) director donates 25,836 shares of common stock
Vanda Pharmaceuticals Inc. director Mitchell Stephen Ray reported a charitable gift of 25,836 shares of common stock, valued at $0.00 per share, using transaction code "G" for a bona fide gift. This donation was made to a charitable organization, and Ray now directly holds 71,246 shares of VNDA common stock. The transaction is a non-market event and does not represent open-market buying or selling activity.
Vanda Pharmaceuticals stock (US92178N1054): Regulatory setback, sharp drop and rising short interest
Vanda Pharmaceuticals (VNDA) shares experienced a significant drop following a regulatory setback announcement and are now seeing increased short interest. The article explores the company's business model, its reliance on a concentrated portfolio of drugs for revenue, and the impact of the regulatory decision on its stock performance and investor sentiment. It highlights the inherent volatility for mid-cap biotechs like Vanda due to regulatory and pipeline risks.
Earnings call transcript: Vanda Pharmaceuticals Q1 2026 misses EPS forecast, stock drops
Vanda Pharmaceuticals reported a challenging Q1 2026, missing EPS and revenue forecasts, which led to a 13.53% drop in its stock price during after-hours trading. The company's EPS loss was $0.82 against an expected $0.69 loss, and revenue reached $51.7 million, below the $55.04 million forecast. Despite strong year-over-year growth for Fanapt, HETLIOZ sales were impacted by generic competition, and the company projects continued challenges with conservative revenue forecasts for upcoming quarters while anticipating positive contributions from new product launches like NEREUS.
State Street (VNDA) discloses 3.02M shares, 5.1% ownership on 13G
State Street Corporation has reported a beneficial ownership of 3,015,562 shares, representing a 5.1% stake in Vanda Pharmaceuticals (VNDA), as detailed in a Schedule 13G filing on March 31, 2026. This filing indicates a passive investment, with shared voting power of 2,935,448 shares and shared dispositive power of 3,015,562 shares, held across multiple State Street advisory entities.
Earnings call transcript: Vanda Pharmaceuticals Q1 2026 misses EPS forecast, stock drops
Vanda Pharmaceuticals reported a challenging Q1 2026, missing EPS and revenue forecasts, which caused a 13.53% stock drop in after-hours trading. Despite a strong annual growth in Fanapt sales, HETLIOZ faced pressure from generic competition. The company is strategically focused on new product launches like NEREUS and BYSANTI to drive future growth.
H.C. Wainwright cuts Vanda Pharmaceuticals stock price target on higher costs
H.C. Wainwright lowered its price target for Vanda Pharmaceuticals (NASDAQ:VNDA) from $24 to $21, while maintaining a Buy rating, due to anticipated higher operating expenses. This adjustment followed the company's Q1 2026 results, where net product sales of $51.7 million missed H.C. Wainwright's forecast, despite a 94% gross profit margin. The analyst report also noted that Vanda Pharmaceuticals had an EPS of -$0.82, missing the -$0.69 forecast, and revenue of $51.7 million, below the anticipated $55.04 million, yet the stock rose in aftermarket trading.
Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences
Vanda Pharmaceuticals Inc. announced its participation in three investor conferences in May 2026: the Bank of America Securities Global Health Care Conference, the HCW 4th Annual BioConnect Investor Conference, and the B. Riley Securities 26th Annual Investor Conference. A fireside chat at the HCW conference will be livestreamed on Vanda's corporate website. The company is focused on developing and commercializing innovative therapies.
Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences
Vanda Pharmaceuticals announced its participation in May 2026 investor conferences. This press release was distributed via Quantisnow, a market data and news platform, which also alerted its Plus members about the announcement. Investors can track Vanda Pharmaceuticals and receive real-time alerts on various market events through Quantisnow.
Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences
Vanda Pharmaceuticals Inc. announced its participation in three investor conferences in May 2026: the Bank of America Securities Global Health Care Conference, the HCW 4th Annual BioConnect Investor Conference, and the B. Riley Securities 26th Annual Investor Conference. A fireside chat at the HCW conference will be broadcast live on Vanda's corporate website. The company is focused on developing and commercializing innovative therapies for unmet medical needs.
Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced its participation in three investor conferences in May 2026. These include the Bank of America Securities Global Health Care Conference, the HCW 4th Annual BioConnect Investor Conference, and the B. Riley Securities 26th Annual Investor Conference. A fireside chat at the HCW conference will be broadcast live on Vanda's corporate website.
Vanda Pharmaceuticals 1Q Loss/Shr 82c >VNDA
Vanda Pharmaceuticals reported a first-quarter loss per share of 82 cents. This financial figure indicates the company's performance for the quarter, reflecting a net loss incurred during that period.
Vanda maps out 3 May investor events, including a live webcast
Vanda Pharmaceuticals (Nasdaq: VNDA) announced its participation in three investor conferences in May 2026: Bank of America Global Health Care (May 12), HCW BioConnect at Nasdaq (May 19), and B. Riley (May 20). A fireside chat will be held on May 19 at the HCW BioConnect event and will be live-streamed and archived on Vanda's investor website. The announcement emphasizes providing additional visibility for investors following recent milestones like the NEREUS™ launch and pivotal imsidolimab data.
Vanda Pharmaceuticals to Participate in Upcoming Investor Conferences
Vanda Pharmaceuticals (VNDA) is scheduled to participate in three investor conferences in May 2026, including the Bank of America Securities Global Health Care Conference and the HCW 4th Annual BioConnect Investor Conference, where it will hold a fireside chat. The company aims to highlight its advancements in biopharmaceuticals, discuss strategic direction, and enhance investor confidence, reinforcing its commitment to transparency and growth in developing therapies for unmet medical needs.
